These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 16959306)
21. Improved abnormal Pap smear triage using cervical cancer biomarkers. Killeen JL; Dye T; Grace C; Hiraoka M J Low Genit Tract Dis; 2014 Jan; 18(1):1-7. PubMed ID: 23760145 [TBL] [Abstract][Full Text] [Related]
22. ThinPrep versus conventional Papanicolaou smear in the cytologic follow-up of women with equivocal cervical smears. Negri G; Menia E; Egarter-Vigl E; Vittadello F; Mian C Cancer; 2003 Dec; 99(6):342-5. PubMed ID: 14681941 [TBL] [Abstract][Full Text] [Related]
23. [Performance of computer-assisted imaging system in detection of squamous intraepithelial lesion of uterine cervix]. Gao YZ; Huo YL; Sun HX; Qi YF; Wang JO; Lü QJ Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):543-6. PubMed ID: 24246921 [TBL] [Abstract][Full Text] [Related]
24. Liqui-Prep® versus conventional Papanicolaou smear to detect cervical cells abnormality by split-sample technique: a randomized double-blind controlled trial. Jesdapatarakul S; Tangjitgamol S; Nguansangiam S; Manusirivithaya S Diagn Cytopathol; 2011 Jan; 39(1):22-7. PubMed ID: 20063407 [TBL] [Abstract][Full Text] [Related]
25. Rapid cervicovaginal smear screening: method of quality control and assessing individual cytotechnologist performance. Pajtler M; Audy-Jurković S; Skopljanac-Macina L; Antulov J; Barisić A; Milicić-Juhas V Cytopathology; 2006 Jun; 17(3):121-6. PubMed ID: 16719854 [TBL] [Abstract][Full Text] [Related]
26. Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study. Westre B; Giske A; Guttormsen H; Wergeland Sørbye S; Skjeldestad FE PLoS One; 2019; 14(11):e0221546. PubMed ID: 31689301 [TBL] [Abstract][Full Text] [Related]
27. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study. Derchain SF; Sarian LO; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo RC; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K J Med Screen; 2008; 15(2):97-104. PubMed ID: 18573778 [TBL] [Abstract][Full Text] [Related]
28. Detection of cervical cancer and high grade neoplastic lesions by a combination of liquid-based sampling preparation and DNA measurements using automated image cytometry. Sun XR; Wang J; Garner D; Palcic B Cell Oncol; 2005; 27(1):33-41. PubMed ID: 15750205 [TBL] [Abstract][Full Text] [Related]
29. A validation study of the FocalPoint GS imaging system for gynecologic cytology screening. Colgan TJ; Bon N; Clipsham S; Gardiner G; Sumner J; Walley V; McLachlin CM Cancer Cytopathol; 2013 Apr; 121(4):189-96. PubMed ID: 23361915 [TBL] [Abstract][Full Text] [Related]
30. Patients with epithelial cell abnormality in PAP smears: correlation of results with follow-up smears and cervical biopsies. Türkmen IÇ; Başsüllü N; Korkmaz P; Günenç B; Baykal CM; Güdücü N; Işçı H; Dünder I; Doğusoy GB Turk Patoloji Derg; 2013; 29(3):179-84. PubMed ID: 24022307 [TBL] [Abstract][Full Text] [Related]
31. The AutoPap system for primary screening in cervical cytology. Comparing the results of a prospective, intended-use study with routine manual practice. Wilbur DC; Prey MU; Miller WM; Pawlick GF; Colgan TJ Acta Cytol; 1998; 42(1):214-20. PubMed ID: 9479343 [TBL] [Abstract][Full Text] [Related]
32. Observer variation in cytologic grading for cervical dysplasia of Papanicolaou smears with the PAPNET testing system. Doornewaard H; van der Schouw YT; van der Graaf Y; Bos AB; van den Tweel JG Cancer; 1999 Aug; 87(4):178-83. PubMed ID: 10455204 [TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic. Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169 [TBL] [Abstract][Full Text] [Related]
35. Low-grade pap smears containing occasional high-grade cells as a predictor of high-grade dysplasia. Power P; Gregoire J; Duggan M; Nation J J Obstet Gynaecol Can; 2006 Oct; 28(10):884-887. PubMed ID: 17140504 [TBL] [Abstract][Full Text] [Related]
36. Performance of the AutoPap Primary Screening System in the detection of high-risk cases in cervicovaginal smears. Alasio LM; Alphandery C; Grassi P; Ruggeri M; De Palo G; Pilotti S Acta Cytol; 2001; 45(5):704-8. PubMed ID: 11575647 [TBL] [Abstract][Full Text] [Related]
37. A feasibility study of the AutoPap system location-guided screening. Lee JS; Kuan L; Oh S; Patten FW; Wilbur DC Acta Cytol; 1998; 42(1):221-6. PubMed ID: 9479344 [TBL] [Abstract][Full Text] [Related]
38. Liquid-based cytology and conventional cervical smears: a comparison study in an Asian screening population. Cheung AN; Szeto EF; Leung BS; Khoo US; Ng AW Cancer; 2003 Dec; 99(6):331-5. PubMed ID: 14681939 [TBL] [Abstract][Full Text] [Related]
39. Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories. Vassilakos P; Saurel J; Rondez R Acta Cytol; 1999; 43(1):65-8. PubMed ID: 9987452 [TBL] [Abstract][Full Text] [Related]
40. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening. Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]